Literature DB >> 14625861

Application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma.

Ali R Shekouh1, Christopher C Thompson, Wendy Prime, Fiona Campbell, Jane Hamlett, C Simon Herrington, Nicholas R Lemoine, Tatjana Crnogorac-Jurcevic, Markus W Buechler, Helmut Friess, John P Neoptolemos, Stephen R Pennington, Eithne Costello.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is the most lethal of all the common malignancies and markers for early detection or targets for treatment of this disease are urgently required. The disease is characterised by a strong stromal response, with cancer cells usually representing a relatively small proportion of the cells in the tumor mass. We therefore performed laser capture microdissection (LCM) to enrich for both normal and malignant pancreatic ductal epithelial cells. Proteins extracted from these cells were then separated by two-dimensional gel electrophoresis (2-DE). The limited amounts of protein in the LCM procured samples necessitated the detection of 2-DE resolved proteins by silver staining. Consequently, loading equivalent amounts of protein onto gels was essential. However, we found that conventional means of measuring total protein in the samples were not sufficiently accurate. We therefore adopted a strategy in which the samples were first separated by one-dimensional sodium dodecyl sulphate-polyacrylamide gel electrophoresis, stained with silver stain and subjected to densitometry. Evaluation of the staining intensity was then used to normalise the samples. We found that the protein profiles from undissected normal pancreas and LCM-acquired non-malignant ductal epithelial cells from the same tissue block were different, underpinning the value of LCM in our analysis. The comparisons of protein profiles from nonmalignant and malignant ductal epithelial cells revealed nine protein spots that were consistently differentially regulated. Five of these proteins showed increased expression in tumor cells while four showed diminished expression in these cells. One of the proteins displaying enhanced expression in tumor cells was identified as the calcium-binding protein, S100A6. To determine the incidence of S100A6 overexpression in pancreatic cancer, we carried out immunohistochemical analysis on sections from a pancreas cancer tissue array containing 174 duplicate normal and malignant pancreatic tissue samples, from 46 pancreas cancer patients. Normal pancreatic ductal epithelia were either devoid of detectable S100A6 or showed weak expression only. Moderately or poorly differentiated tumors, by contrast, showed a higher incidence and a higher level of S100A6 expression. These observations indicate that the combination of LCM with 2-DE provides an effective strategy to discover proteins that are differentially expressed in PDAC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14625861     DOI: 10.1002/pmic.200300466

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  40 in total

Review 1.  Identifying molecular markers for the early detection of pancreatic neoplasia.

Authors:  Michael Goggins
Journal:  Semin Oncol       Date:  2007-08       Impact factor: 4.929

Review 2.  [Proteome analysis--basis for individualized pancreatic carcinoma therapy?].

Authors:  J M Löhr; R Faissner; P Findeisen; M Neumaier
Journal:  Internist (Berl)       Date:  2006-06       Impact factor: 0.743

3.  Proteome analysis of human pancreatic ductal adenocarcinoma tissue using two-dimensional gel electrophoresis and tandem mass spectrometry for identification of disease-related proteins.

Authors:  Rui Tian; Li-Ming Wei; Ren-Yi Qin; Yan Li; Zhi-Yong Du; Wei Xia; Cheng-Jian Shi; Hong Jin
Journal:  Dig Dis Sci       Date:  2007-05-11       Impact factor: 3.199

4.  Proteomic analysis to identify cytokeratin 18 as a novel biomarker of nasopharyngeal carcinoma.

Authors:  Xiang-Min Li; Wei-Guo Huang; Hong Yi; Ai-Lan Cheng; Zhi-Qiang Xiao
Journal:  J Cancer Res Clin Oncol       Date:  2009-06-16       Impact factor: 4.553

5.  A proteomic investigation into adriamycin chemo-resistance of human leukemia K562 cells.

Authors:  Xingchen Peng; Fengming Gong; Gang Xie; Yuwei Zhao; Minghai Tang; Luoting Yu; Aiping Tong
Journal:  Mol Cell Biochem       Date:  2011-01-18       Impact factor: 3.396

6.  Differentiation of multiple types of pancreatico-biliary tumors by molecular analysis of clinical specimens.

Authors:  Thomas M Gress; Hans A Kestler; Ludwig Lausser; Lisa Fiedler; Bence Sipos; Christoph W Michalski; Jens Werner; Nathalia Giese; Aldo Scarpa; Malte Buchholz
Journal:  J Mol Med (Berl)       Date:  2011-11-26       Impact factor: 4.599

7.  Characterization of Molecular Markers Indicative of Cervical Cancer Progression.

Authors:  Hilal Arnouk; Mark A Merkley; Robert H Podolsky; Hubert Stöppler; Carlos Santos; Manuel Alvarez; Julio Mariategui; Daron Ferris; Jeffrey R Lee; William S Dynan
Journal:  Proteomics Clin Appl       Date:  2009-05-05       Impact factor: 3.494

8.  Use of combination proteomic analysis to demonstrate molecular similarity of head and neck squamous cell carcinoma arising from different subsites.

Authors:  Paul M Weinberger; Mark Merkley; Jeffrey R Lee; Bao-Ling Adam; Christine G Gourin; Robert H Podolsky; Bruce G Haffty; Evangelia Papadavid; Clarence Sasaki; Amanda Psyrri; William S Dynan
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2009-07

9.  Target proteomic profiling of frozen pancreatic CD24+ adenocarcinoma tissues by immuno-laser capture microdissection and nano-LC-MS/MS.

Authors:  Jianhui Zhu; Song Nie; Jing Wu; David M Lubman
Journal:  J Proteome Res       Date:  2013-05-29       Impact factor: 4.466

10.  S100A6 binds to annexin 2 in pancreatic cancer cells and promotes pancreatic cancer cell motility.

Authors:  T Nedjadi; N Kitteringham; F Campbell; R E Jenkins; B K Park; P Navarro; F Ashcroft; A Tepikin; J P Neoptolemos; E Costello
Journal:  Br J Cancer       Date:  2009-09-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.